It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Home > Dosing

Are you tailoring their dosing for optimal treatment outcomes?

A complete blood cell count, including a white blood cell count differential, must be performed prior to treatment initiation[1]

Graphic depicting dosing guidance for JAKAVI, including starting dose by platelet level, maintenance dosing, and recommended adjustments.
Graphic depicting dosing guidance for JAKAVI, including starting dose by platelet level, maintenance dosing, and recommended adjustments.
Graphic depicting dosing guidance for JAKAVI, including starting dose by platelet level, maintenance dosing, and recommended adjustments.
MF_Dosing_Recos

In PV, dose reductions should also be considered if haemoglobin decreases below 12g/dl and is recommended if it decreases below 10g/dl

Explore symptom improvement with JAKAVI
See the survival rates regardless of anaemia status
Learn more about myelofibrosis

Reference

  1. JAKAVI® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; January 2022.

This is an international website for JAKAVI® (ruxolitinib) and is intended for healthcare professionals outside of the United States. If you are a U.S. resident, please click here or on the U.S. Residents link on this page.

© 2025 Novartis Pharma AG. All rights reserved.
117343-2 6/22
Use of this website is subject to our Terms of Use.